Yes, I see where you are coming from with that. The clinical trials should be the really expensive part and the analysis should be at a lower cost.
There will be other expenses - and general non research expenses look like they are over $200k per quarter.
BIT will still need to create more cash moving forward so, it is prudent to have a CR soon. All companies do that and BIT will have to set itself up for the immediate future. CR is not a dirty word - just a management tool
Thanks for pointing that out.
$30 Billion Deal, page-4688
-
- There are more pages in this discussion • 392 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
